Hematological Recovery Persistent for More Than 1 Yearin an Elderly Patient with Acute Monoblastic Leukemiaafter Severe Bone Marrow Suppression Induced by Oral Induction Therapy-Reference-Cited by-同舟云学术

Hematological Recovery Persistent for More Than 1 Yearin an Elderly Patient with Acute Monoblastic Leukemiaafter Severe Bone Marrow Suppression Induced by Oral Induction Therapy

Published:2021-10-01 Issue:5 Volume:80 Page:243-245
ISSN:0029-0424
Container-title:Journal of Nihon University Medical Association
language:en
Short-container-title:Nichidai Igaku Zasshi

Author:

Horikoshi Akira¹

Affiliation:

1. Department of General Internal Medicine, Japan Association for Development of Community Medicine, Nerima-Hikarigaoka Hospital

Publisher

The Nihon University Medical Association

Link

https://www.jstage.jst.go.jp/article/numa/80/5/80_243/_pdf

Reference6 articles.

1. 1） Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116: 4422– 4429.

2. 2） Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML > 30% blasts. Blood 2015; 126: 291–299.

3. 3） Horikoshi A, Takei K, Hosokawa Y, et al. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int J Hematol 2008; 87: 118–125.

4. 4） Horikoshi A, Iriyama N, Hirabayashi Y, et al. Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients. Chemotherapy 2013; 59: 152–158.

5. 5）玉井勇人，猪口孝一．11q23 転座型急性白血病の予後と治療．臨床血液 2008; 49: 193–200.